Skip to content
Adjuvance Technologies

Adjuvance Technologies

Empowering health.

  • Our Technology
  • Our Leadership
    • Management Team
    • Board of Directors
  • Investors & Media
  • Contact

Blog

Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine

April 1, 2016Publications

In a preclinical model, GSK scientists report a greater immune response to GSK Shingles vaccine (Hz/su) formulations that contain QS-21.

Read More

Posts navigation

Older posts

Recent Posts

  • Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine
  • NEJM Reports Efficacy of QS-21 Containing Herpes Zoster Subunit Vaccine
  • Vaccine Adjuvant Systems containing monophosphoryl lipid A andQS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination
  • Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol
  • Nature Chemistry: Development of a minimal saponin vaccine adjuvant based on QS-21
Copyright © All rights reserved. Theme Businessbiz by Sensational Theme